The aim of the study was to assess inhaler preference for and handling errors with the ELLIPTA dry powder inhaler ( DPI ) , ( GSK ) , compared with the established BREEZHALER , a single-dose capsule DPI ( Novartis ) , in inhalation device-nave Japanese volunteers aged 40 years .